Suzanne Lentzsch
Director, Multiple Myeloma and Amyloidosis Program · Columbia University Medical Center
Credentials: · · · ·
History
- Present
Multiple Myeloma and Amyloidosis Program · Columbia University Medical Center
- Present
Columbia University Irving Medical Center/NewYork-Presbyterian Hospital
Research
Review · The Lancet Oncology · 2016 · 2,602 citations
Blood · 2001 · 777 citations
IMWG consensus on risk stratification in multiple myeloma
Review · Leukemia · 2014 · 502 citations
51 papers
46 papers
45 papers
18 papers
17 papers
16 papers
15 papers
- BD
15 papers
Grants
- 2024–2029
CUIMC Calabresi Clinical Oncology Career Development Program
National Cancer Institute · K12
PI · $1.5M · Columbia University Health Sciences
- 2021–2027
National Cancer Institute · R01
Contact PI · $2.4M · Columbia University Health Sciences
- 2020–2023
Screening to Improve Survival in AL Amyloidosis
National Institute on Aging · R21
PI · $515.3K · Tufts Medical Center
- 2013–2019
The Role of MMP13 in Multiple Myeloma Bone Disease
National Cancer Institute · R01
Contact PI · $1.7M · Columbia University Health Sciences
Clinical trials
- 2013–2023
Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
Principal investigator · Terminated · Phase 1, Phase 2
Suzanne Lentzsch, MD
- 2013–2019
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
Principal investigator · Completed · Phase 2
Columbia University
- 2012–2017
Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
Principal investigator · Completed · Phase 4
Columbia University
- 2008
Study chair · Completed
Eastern Cooperative Oncology Group